

## INFORMATIONAL STATEMENT

The informational statement required by NRS 233B.066 numerically conforms to the subsections of the statute as follows:

### 1. EXPLANATION OF THE NEED FOR THE ADOPTED REGULATION

The proposed regulations will authorize a pharmacist to prescribe, dispense, and administer certain drugs approved by the United States Food and Drug Administration for preventing the acquisition of human immunodeficiency virus under a protocol. Implementing these regulations will expand access to pre-exposure and post-exposure human immunodeficiency preventative medications.

### 2. A DESCRIPTION OF HOW PUBLIC COMMENT WAS SOLICITED, A SUMMARY OF PUBLIC RESPONSE, AND AN EXPLANATION HOW OTHER INTERESTED PERSONS MAY OBTAIN A COPY OF THE SUMMARY.

The Board solicited comment on the proposed amendment by (1) posting notice, with links to the full text of the proposed amendment, to the LCB Administrative Regulation Notices webpage, (2) posting a copy of the full text of the proposed changes to the Board's website as part of the Board Hearing materials, (3) posting notice to the Nevada Public Notice website, operated by the Department of Administration, with a link back to a full text of the proposed amendment on the Board's website, and (4) posting notices and agendas in numerous public locations per NRS Chapter 233B.

The Board also solicited comment from Nevada dispensing practitioners, and from representatives of relevant industry associations that Board Staff deemed likely to have an interest in the proposed amendment. The Board further provided time for public comment at the workshop(s) concerning the proposed amendment.

Elizabeth MacMenamin, VP, Government Affairs  
Retail Association of Nevada  
410 S. Mountain Street  
Carson City, NV 89703 – (775-882-1700)  
LizM@rannv.org

Ms. MacMenamin spoke in support of the proposed amendments. She is looking forward to moving the proposed amendments forward so patients can be treated in a timely manner.

Ken Kunke, Nevada Pharmacy Alliance  
702-714-1931  
info@nevadapharmacyalliance.com  
11 Sunset Way, Henderson, NV 89014

Mr. Kunke spoke in support of the proposed amendments. He commented that he is excited about pharmacists helping patients in Nevada.

Parties interested in obtaining a copy of the summary of the proposed amendment, or that wish to view the text of the proposed amendment, may access that information on the Board's website at [bop.nv.gov](http://bop.nv.gov), or by contacting the Board's office at (775) 850-1440.

3. THE NUMBER OF PERSONS WHO: (A) ATTENDED EACH HEARING; (B) TESTIFIED AT EACH HEARING; AND (C) SUBMITTED TO THE AGENCY WRITTEN STATEMENTS.

The number of persons who attended the hearing was: -54-

The number of persons who testified at the hearing was: -2-

The number of agency submitted statements was: -0-

The name of persons who testified at the hearing:

Elizabeth MacMenamin, VP, Government Affairs  
Retail Association of Nevada  
410 S. Mountain Street  
Carson City, NV 89703 – (775-882-1700)  
LizM@rannv.org

Ms. MacMenamin spoke in support of the proposed amendments. She is looking forward to moving the proposed amendments forward so patients can be treated in a timely manner.

Ken Kunke, Nevada Pharmacy Alliance  
702-714-1931  
info@nevadapharmacyalliance.com

11 Sunset Way, Henderson, NV 89014

Mr. Kunke spoke in support of the proposed amendments. He commented that he is excited about pharmacists helping patients in Nevada.

4. A DESCRIPTION OF HOW COMMENT WAS SOLICITED FROM AFFECTED BUSINESSES, A SUMMARY OF THEIR RESPONSE, AND AN EXPLANATION HOW OTHER INTERESTED PERSONS MAY OBTAIN A COPY OF THE SUMMARY.

The Board solicited comment on the proposed amendment by (1) posting notice, with links to the full text of the proposed amendment, to the LCB Administrative Regulation Notices webpage, (2) posting a copy of the full text of the proposed changes to the Board's website as part of the Board Hearing materials, (3) posting notice to the Nevada Public Notice website, operated by the Department of Administration, with a link back to a full text of the proposed amendment on the Board's website, and (4) posting notices and agendas in numerous public locations per NRS Chapter 233B.

The Board also solicited comment from Nevada dispensing practitioners, and from representatives of relevant industry associations that Board Staff deemed likely to have an interest in the proposed amendment. Further, the Board provided time for public comment at the workshop(s) concerning the proposed amendment.

Elizabeth MacMenamin, VP, Government Affairs  
Retail Association of Nevada  
410 S. Mountain Street  
Carson City, NV 89703 – (775-882-1700)  
LizM@rannv.org

Ms. MacMenamin spoke in support of the proposed amendments. She is looking forward to moving the proposed amendments forward so patients can be treated in a timely manner.

Ken Kunke, Nevada Pharmacy Alliance  
702-714-1931  
info@nevadapharmacyalliance.com  
11 Sunset Way, Henderson, NV 89014

Mr. Kunke spoke in support of the proposed amendments. He commented that he is excited about pharmacists helping patients in Nevada.

Parties interested in obtaining a copy of the summary of the proposed amendment, or that wish to view the text of the proposed amendment, may access that information on the Board's website at [bop.nv.gov](http://bop.nv.gov), or by contacting the Board's office at (775) 850-1440.

5. IF THE REGULATION WAS ADOPTED WITHOUT CHANGING ANY PART OF THE PROPOSED REGULATION, A SUMMARY OF THE REASONS FOR ADOPTING THE REGULATION WITHOUT CHANGE.

The Board received no comments from industry or the public requesting any changes.

6. THE ESTIMATED ECONOMIC EFFECT OF THE REGULATION ON THE BUSINESS WHICH IT IS TO REGULATE AND ON THE PUBLIC. THESE MUST BE STATED SEPARATELY, AND IN EACH CASE MUST INCLUDE:
  - A) BOTH ADVERSE AND BENEFICIAL EFFECTS.

There should be no adverse economic impact from these regulations on the regulated entities or on the public. The beneficial effects on regulated entities and the public will be to expand access to pre-exposure and post-exposure human immunodeficiency preventative medications.

- B) BOTH IMMEDIATE AND LONG-TERM EFFECTS.

Both the immediate and long-term economic effects on regulated entities and on the public will be expanded access to pre-exposure and post-exposure human immunodeficiency preventative medications.

7. THE ESTIMATED COST TO THE AGENCY FOR ENFORCEMENT OF THE PROPOSED REGULATION.

There will be no additional or special costs incurred by the Board of Pharmacy for enforcement of this regulation amendment.

8. A DESCRIPTION OF ANY REGULATIONS OF OTHER STATE OR GOVERNMENT AGENCIES WHICH THE PROPOSED REGULATION OVERLAPS OR DUPLICATES AND A STATEMENT EXPLAINING WHY THE DUPLICATION OR OVERLAPPING IS NECESSARY. IF THE REGULATION OVERLAPS OR DUPLICATES A FEDERAL REGULATION, THE NAME OF THE REGULATING FEDERAL AGENCY.

The Board of Pharmacy is not aware of any similar regulations of other state or government agencies that the proposed regulation overlaps or duplicates.

9. IF THE REGULATION INCLUDES PROVISIONS WHICH ARE MORE STRINGENT THAN A FEDERAL REGULATION WHICH REGULATES THE SAME ACTIVITY, A SUMMARY OF SUCH PROVISIONS.

The regulation does not contain provisions which are more stringent than a federal regulation which regulates the same activity.

10. IF THE REGULATION PROVIDES A NEW FEE OR INCREASES AN EXISTING FEE, THE TOTAL ANNUAL AMOUNT THE AGENCY EXPECTS TO COLLECT AND THE MANNER IN WHICH THE MONEY WILL BE USED.

This regulation does not provide a new or increase of fees.